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Improving affordability of new Essential Cancer Medicines
Effective cancer care requires investment in health 
infrastructure, a trained health workforce, and quality-
assured, affordable medicines within a sustainable 
supply chain. To this end, in a major move to increase 
access to cancer medicines in low-income and middle-
income countries (LMICs), WHO has added ten new 
cancer therapies to its 21st Model List of Essential 
Medicines.1 When WHO labels medicines as essential, 
it means that they have proven their utility and should 
be available and affordable to all. Therefore, these 
medicines should be included in national essential 
medicines lists, which would enable governments 
to use scarce resources to select medicines more 
effectively.
Including cancer medicines in the WHO Essential 
Medicines List is the crucial first step. Effective 
national policies incorporating legal and regulatory 
frameworks that promote access are needed to make 
cancer diagnosis and treatment widely available.2 
Cancer medicines often come at a high price, creating 
challenges even for high income countries (HICs), while 
their availability in LMICs is limited or non-existent. 
The new WHO Essential Medicines List should prompt 
governments and other stakeholders to take action to 
decrease the price of medicines in order to make them 
accessible.
The situation of lenalidomide in South Africa is a 
case in point. Lenalidomide is an essential medicine 
for the treatment of multiple myeloma. Until 
2016, South African patients had access to generic 
lenalidomide manufactured in India under a section 
21 legal authorisation that allows the sale and use 
of unregistered products. The generic lenalidomide 
was priced at US$2289 per patient per year. This 
authorisation was withdrawn when Celgene registered 
its patented product in the country and priced it at 
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agents, including the rocket fuel hydrazine and the 
burning of wood fuel in the home. These examples 
illustrate how far this classification is from defining the 
detailed real-world risks. Rocket-testing workers can be 
exposed to hydrazine, but most of us will never come 
upon it. And the risk from your wood-burning stove 
clearly depends in a complicated way on the wood, the 
stove, and how much you use it.
The remaining doubt on shift working is largely 
because clear evidence in humans is very hard to 
obtain. There is good evidence, IARC conclude, 
that interfering with rhythms of light and dark in 
experimental animals can increase the probability of 
cancer, and indeed on how these changes occur. But 
do things work in the same way in humans? There 
are inconsistencies in the evidence. It is not ethical or 
feasible to carry out long-term experiments in humans, 
so instead researchers observe people, and record their 
working patterns and cancer diagnoses. Unavoidably, 
there are many possible biases in such studies. Perhaps 
the people studied are not typical, or their work records 
were inaccurate. Also, people who work shifts differ 
from those who do not in many ways, and perhaps 
these other differences are the real cause of any 
increase in cancer risk. 
The IARC assessment, “probably carcinogenic in 
humans”, has not changed since they last considered 
shift working in 2007. They have certainly considered 
much new evidence; all but one of their references 
describe work published since 2007. But the new 
evidence from human studies still has unavoidable 
inconsistencies and potential biases. Future research 
might make things clearer, but that will not be easy.
Should you be concerned by this classification if you 
work night shifts? IARC have left open the possibility 
that shift working has no effect at all on cancer risk. If 
it has, the evidence on the size of any risk is not clear. 
If the risks were really substantial, the research results 
in humans could well have been clearer and more 
consistent. My feeling is that this should not be a major 
worry for night shift workers.
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$51 000 per patient per year. The medicine is now 
no longer available in the public sector, which cares 
for 84% of the population. Patients in the private 
sector are also struggling to pay the 20% co-payment. 
In India, however, where the patent application for 
lenalidomide was rejected, the generic versions are 
available for $2000 per patient per year.3 Another 
example is afatinib, which is a first-line tyrosine kinase 
inhibitor used to treat lung cancer, the leading cause 
of death from cancer in men in LMICs and the second 
leading cause after breast cancer in women.4 Afatinib, 
now listed in the Essential Medicines List as equivalent 
to erlotinib, is not widely available in LMICs, and when 
this medicine is available, its price is a major challenge 
to access. For example, in Pakistan, where afatinib costs 
over $1000 per month of treatment,5 many patients 
cannot afford it.
Studies on the cost of production of cancer medicines 
show that substantial reduction in price is possible. 
Using a validated algorithm6 for estimating the cost 
of production, accounting for tax and a 10% profit 
margin, it is estimated that lenalidomide could cost 
$2·55 per month, afatinib could cost $8·85 per month, 
and abiraterone $60·97 per month.
The drive to lower the price for medicines is always 
met by concern about the loss of revenue to finance 
the research and development sector. Yet the global 
sales figures for medicines that have been on the 
market in HICs further provide evidence that this 
concern is unwarranted. For instance, cumulative sales 
incomes of cancer medicines in 2017 for trastuzumab 
and rituximab were $88·18 billion and $93·74 
billion, respectively. WHO studied sales revenue from 
99 cancer medicines approved by the FDA from 1989 
to 2017, illustrating that the average financial return 
on investment was $14·50 for every $1 of spending. 
A third of the cancer medicines studied had already 
reached blockbuster status with over $1 billion annual 
sales income.7 Most of these sales take place in HICs. 
Therefore, making these new medicines affordable 
in LMICs is not likely to impair future research and 
development.
Countries could take some of the following measures 
to improve access to cancer medicines, including new 
paediatric cancer drugs: pooling their procurement at 
the regional or subregional level to create economies 
of scale and increase their negotiating power, 
encouraging sustainable supply of low-cost generics8 
and the uptake of biosimilars, and using flexibility in 
trade-related aspects of intellectual property rights 
(TRIPS) agreements to lift a patent monopoly when 
needed to access generics. Pharmaceutical companies 
should also engage in public health oriented voluntary 
licensing of products through the Medicines Patent 
Pool. There is ample evidence that the abovementioned 
options work in other fields, notably in the area of HIV 
and hepatitis C virus.9,10
Countries will continue to need the support of WHO 
in expanding cancer care and treatment. WHO’s pivotal 
report on cancer medicines pricing necessitates that the 
organisation steps up its attention on cancer care and 
translates these efforts into forceful strategies.
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Globally, more than 18 million new cases of cancer 
were diagnosed in 2018, and almost 10 million 
deaths were registered.1 In the occupied Palestinian 
territory (the West Bank and Gaza Strip), cancer is the 
second most common cause of death exceeded only 
by heart disease.2 Most cases are diagnosed at a late 
stage, leading to difficulties in symptom control and 
treatment options, and compromising quality of life 
and survival.3
As of April, 2019, 5 163 667 people live in the occupied 
Palestinian territory, according to UN estimates. 
Two million people are living in the Gaza Strip, 
which is a narrow, overcrowded strip of land located 
southwest of the West Bank, measuring 362 km² and 
with a population density of 5525 people per km². 
75% of the population live below the poverty line and 
unemployment was 52% in 2018 (an increase of 8% 
from 2017) according to the Palestinian Central Bureau 
of Statistics.4
There are only two oncology departments in the 
Gaza Strip, one at Ranteesy Hospital and another 
at the European Gaza Hospital. Cancer therapy 
generally includes surgical treatment, chemotherapy, 
and radiotherapy or combination therapy, in addition to 
auxiliary services, such as radio-diagnostics, laboratory 
services, and nuclear medicine.5 However, medical 
facilities in the Gaza Strip suffer chronic shortages of 
many essential medicines, due in part to the complex 
and ongoing sociopolitical and economic crises faced 
by the Ministry of Health, as well as political instability 
and lack of funding.6 On average, 30–40% of essential 
chemotherapy drugs are out of stock at any one time 
in Gaza.7 The unavailability of systemic treatment 
affects 7415 (60%) of 12 359 patients. Missing just one 
chemotherapy dose or cycle can dramatically decrease 
the effectiveness of the treatment and increase the risk 
of drug resistance in patients.8
Surgery is the main cancer intervention in Gaza. It is 
sometimes the first and often the last modality used 
to treat cancer in Gaza, usually due to the absence of 
other options. More than 85% of surgical treatment 
of cancer is done without adjuvant or neoadjuvant 
chemotherapy, owing to the shortage of these drugs. 
Radiotherapy is still unavailable throughout the Gaza 
Strip. Radioisotopes and radioactive substances used 
for diagnosis and radiotherapy services, which are 
crucial, for example, for biopsying axillary lymph nodes 
and therefore assessing the spread of breast cancer, are 
banned from entering the Gaza Strip.
The high number of patients with cancer in oncology 
wards and the delay in receiving adequate cancer 
treatment force the medical staff to look for other 
options, such as referring patients for treatment 
outside Gaza in other countries.9 This option has 
several drawbacks. More than 60% of patients 
are prohibited from entering these countries by 
governments. For the remaining 40% of patients, 
even if they do manage to travel, their treatment is 
a substantial financial burden on health authorities, 
as well as the patients themselves and their families. 
There is also a substantial social and psychological 
burden. Further, referrals are usually delayed during 
travelling, which leads to deterioration of the patient’s 
condition, and sometimes death.
A lack of epidemiological studies and reliable data 
motivated us to do a retrospective assessment of the 
cancer burden in the low-income, isolated territory (the 
Gaza Strip) within the occupied Palestinian territory. 
We calculated the total number of new annual cancer 
cases during the past 8 years (2011–2018). Annual 
cancer incidence, strategic treatment intervention, and 
mortality were also calculated.
We found 12 359 new cancer cases in the Gaza Strip 
between 2011 and 2018. Of the five governorates of 
the Gaza Strip, Gaza City had the most cancer cases 
(5685 [46·0%] of 12 359), followed by Khanyounis 
(2101 [17·0%]), Deir al-Balah (1644 [13·3%]), north 
Gaza (1508 [12·2%]), and Rafah (1421 [11·5%]). The 
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